7th Oct 2015 06:43
LONDON (Alliance News) - Pharmaceuticals giant AstraZeneca PLC on Wednesday said it has completed the divestment of its Caprelsa rare disease medicine to Genzyme, a unit of French drugmaker Sanofi SA.
Genzyme has made an upfront payment of USD165 million to AstraZeneca for the global rights to develop and sell the drug, and will make further payments of up to USD135 million.
Caprelsa was granted Orphan Drug Designation by the US Food and Drug Administration in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, AstraZeneca said when announcing the deal in July.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca